Working… Menu

Effect of Leptin Therapy in the Treatment of Severe Insulin Resistance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00085982
Recruitment Status : Recruiting
First Posted : June 21, 2004
Last Update Posted : December 14, 2020
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) )

Brief Summary:

Leptin is a hormone produced by the fat cells that researchers have shown to play a role in controlling appetite. Certain people with severe insulin resistance have little or no leptin.

The purpose of this study is to investigate people whose leptin levels have been found to be lower than 85 percent of the general population. Researchers will determine whether insulin levels in these participants improve when they are treated with genetically engineered leptin.

Study participants must be age 8 years or older and must have severe insulin resistance syndrome and leptin deficiency. During an initial 7-day visit to the Clinical Center, researchers will evaluate participants' metabolic parameters, such as insulin responsiveness, lipid levels, appetite, and hormone levels. After taking these tests, participants will self-inject doses of leptin once or twice a day and will be monitored for treatment outcomes as well as side effects via follow-up visits. These inpatient follow-up visits will involve both blood tests and imaging studies at the Clinical Center at 4, 8, and 12 months after the initial visit, and every 6 months thereafter.

Condition or disease Intervention/treatment Phase
Severe Insulin Resistance Drug: Metreleptin Phase 2

Detailed Description:

Study Description:

Patients with mutations of the insulin receptor have diabetes that is challenging to control withconventional therapies, leading to early morbidity and mortality. We hypothesize that recombinant leptin (metrel eptin) in these patients will improve glycemia control.


Primary Objective: To determine if 1 year of metreleptin will improve glycemia control in patients with genetic defects of the insulin receptor. Secondary Objectives: To determine mechanisms by which metreleptin improves glycemia.


Primary Endpoint: Hemoglobin A1c

Secondary Endpoints: fasting plasma glucose, fasting insulin, glucose/insulin area under the curve during oral glucose tolerance test.

Study Population:

20 male or female patients with mutations of the insulin receptor, age (Bullet)5 years, at the NIH Clinical Center.

Description of Sites/Facilities Enrolling Participants: Description of Study Intervention:

NIH Clinical Center

Open label study of metreleptin, 0.2 mg/kg/day (max dose 0.24 mg/kg/day).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pase II Trial of Effect of Leptin Therapy in Severe Insulin Resistance
Actual Study Start Date : August 21, 2003
Estimated Primary Completion Date : January 1, 2030
Estimated Study Completion Date : January 1, 2030

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Leptin Treatment
300 mg of study drug administered via SC injections.
Drug: Metreleptin
Administered SQ twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin rece

Primary Outcome Measures :
  1. Improvements in HbA1c, fasting blood glucose, and fasting insulin levels [ Time Frame: Every 6-12 months ]
    Lower HbA1C, lower blood glucose values, & lower insulin levels.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged > 5 years
  • Clinically significant, severe insulin resistance caused by a known or suspected defect in the insulin receptor
  • Presence of at least one of the following metabolic abnormalities:

    • Fasting insulin >30 micro U/ml, or
    • Presence of diabetes as defined by the 2006 ADA criteria:

      • Fasting plasma glucose >= 126 mg/dL
      • 2 hour plasma glucose >= 200 mg/dL following a 75 gram (1.75g/kg if less than 40kg) oral glucose load, or
      • Diabetic symptoms with a random plasma glucose >= 200 mg/dL


  • Pregnant at time of enrollment, women in their reproductive years who do not use an effective method of birth control, and women currently nursing or lactating within 6 weeks of having completed nursing.
  • Known infectious liver disease
  • Known HIV infection
  • Current alcohol or substance abuse
  • Psychiatric disorder impeding competence or compliance
  • Active tuberculosis
  • Use of anorexiogenic drugs
  • Other conditions which in the opinion of the clinical investigators would impede completion of the study.
  • Subjects who have a known hypersensitivity to E. Coli derived proteins.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00085982

Layout table for location contacts
Contact: Megan S Startzell, R.N. (301) 402-6371
Contact: Rebecca J Brown, M.D. (301) 594-0609

Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Layout table for investigator information
Principal Investigator: Rebecca J Brown, M.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Identifier: NCT00085982    
Other Study ID Numbers: 030257
First Posted: June 21, 2004    Key Record Dates
Last Update Posted: December 14, 2020
Last Verified: October 27, 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ):
Rabson Mendenhall
Type B Insulin Resistance
Type A Insulin Resistance
Additional relevant MeSH terms:
Layout table for MeSH terms
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases